Funding Themes

Funding Themes

The CARB-X 2022-2023 funding rounds had three distinct product themes as described below.

Register for the CARB-X newsletter to receive information about new funding rounds that will be announced in 2024.

Icons for Oral therapeutics, vaccines for neonatal sepsis, and gonnorrhea products

Icon for Oral Products

Oral therapeutics:

The scope was restricted to oral products addressing specific syndromes and causative agents possible, including:

  • Stepdown for respiratory tract infections caused primarily by Gram-negative pathogens, including antibiotic-resistant strains (see Target Product Profile);
  • Safe therapy for infections caused primarily by Gram-positive organisms, including antibiotic-strains (see Target Product Profile); or
  • Safe therapy for urinary tract infections, including those caused by antibiotic-resistant bacteria (see Target Product Profile).

In all cases, activity against multidrug-resistant isolates of pathogens specified in the Target Product Profiles was essential.

Icon for neonatal sepsis

Vaccines for neonatal sepsis:

The scope was restricted to vaccines focused on the prevention of neonatal sepsis, targeting one or more of the following organisms (see Target Product Profile):

  • Klebsiella pneumoniae (highest priority);
  • Escherichia coli (ETEC or urinary);
  • Acinetobacter baumannii; and
  • Staphylococcus aureus.

While a maternal vaccine was sought, an additional commercial indication was considered.

Icon for Gonorrhea products

Gonorrhea products:

The scope was open to products that address Neisseria gonorrhoeae, including, for example:

Therapeutic and vaccine products were required to address both drug-sensitive and drug-resistant scenarios.